Your browser doesn't support javascript.
loading
DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.
Prompetchara, Eakachai; Ketloy, Chutitorn; Tharakhet, Kittipan; Kaewpang, Papatsara; Buranapraditkun, Supranee; Techawiwattanaboon, Teerasit; Sathean-Anan-Kun, Suwitra; Pitakpolrat, Patrawadee; Watcharaplueksadee, Supaporn; Phumiamorn, Supaporn; Wijagkanalan, Wassana; Patarakul, Kanitha; Palaga, Tanapat; Ruxrungtham, Kiat.
Afiliación
  • Prompetchara E; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Ketloy C; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Tharakhet K; Integrated Frontier Biotechnology for Emerging Disease, Chulalongkorn University, Bangkok, Thailand.
  • Kaewpang P; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Buranapraditkun S; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Techawiwattanaboon T; Integrated Frontier Biotechnology for Emerging Disease, Chulalongkorn University, Bangkok, Thailand.
  • Sathean-Anan-Kun S; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Pitakpolrat P; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Watcharaplueksadee S; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Phumiamorn S; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Wijagkanalan W; Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Patarakul K; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Palaga T; Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Ruxrungtham K; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
PLoS One ; 16(3): e0248007, 2021.
Article en En | MEDLINE | ID: mdl-33750975
More than 65 million people have been confirmed infection with SARS-CoV-2 and more than 1 million have died from COVID-19 and this pandemic remains critical worldwide. Effective vaccines are one of the most important strategies to limit the pandemic. Here, we report a construction strategy of DNA vaccine candidates expressing full length wild type SARS-CoV-2 spike (S) protein, S1 or S2 region and their immunogenicity in mice. All DNA vaccine constructs of pCMVkan-S, -S1 and -S2 induced high levels of specific binding IgG that showed a balance of IgG1/IgG2a response. However, only the sera from mice vaccinated with pCMKkan-S or -S1 DNA vaccines could inhibit viral RBD and ACE2 interaction. The highest neutralizing antibody (NAb) titer was found in pCMVkan-S group, followed by -S1, while -S2 showed the lowest PRNT50 titers. The geometric mean titers (GMTs) were 2,551, 1,005 and 291 for pCMVkan-S, -S1 and -S2, respectively. pCMVkan-S construct vaccine also induced the highest magnitude and breadth of T cells response. Analysis of IFN-γ positive cells after stimulation with SARS-CoV-2 spike peptide pools were 2,991, 1,376 and 1,885 SFC/106 splenocytes for pCMVkan-S, -S1 and -S2, respectively. Our findings highlighted that full-length S antigen is more potent than the truncated spike (S1 or S2) in inducing of neutralizing antibody and robust T cell responses.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 4_pneumonia Asunto principal: Células TH1 / Vacunas de ADN / Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Tailandia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 4_pneumonia Asunto principal: Células TH1 / Vacunas de ADN / Inmunidad Humoral / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Tailandia
...